-
Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
Thursday, June 28, 2018 - 11:42am | 408The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but...